

Figure S1




Figure S2




Figure S3

Concentration (μM)


A

	ABT-263	A115	PPL
S1	0,3125	0,078125	0,15625
S2	0,625	0,15625	0,3125
S3	1,25	0,3125	0,625
S4	2,5	0,625	1,25
S5	5	1,25	2,5


B

LnCaP


No
senolytic
(S0)




XRA



PARPi




ABT-263
(S3)




PC-3


Untreated






XRA



PARPi



A-115
(S3)



PPL
(S3)








Figure S4

A



B



C






Figure S5


A




B



C




D




E



F



G



H




Figure S6

A

LnCaP



**B**

Table S1

Target	Forward (5'-3')	Reverse (5'-3')
p15	GAATGCGCGAGGAGAACAAAG	CATCATCATGACCTGGATCGC
p16	GGGAGCAGCATGGAGCCT	ATGACCTGGATCGGCCTCCGACCGT
p21	GGGACAGCAGAGGAAGAC	TGGAGTGGTAGAAATCTGTCA
p27	TCCGGCTAACTCTGAGGACA	GTAGAAGAACATGTCGGTTGC
p53	GGAAGACTCCAGTGGTAATCTA	TTGGGCAGTGCTCGCTTA
p57	GCGGTGAGCCAATTAGAGC	CGGTTGCTGCTACATGAACG
IL-8	GCCAACACAGAAATTATTGTAAG	TTATGAATTCTCAGCCCTTTC
IL-6	TGTGTGAAAGCAGCAAAGA	GGCAAGTCTCCTCATTGAA
Il-1 α	ACCAGTGCTGCTGAAGGAGAT	TCTTAGTGCCGTGAGTTCCC
IL-1 β	AGAAGTACCTGAGCTGCCA	CTGGAAGGAGCACCTCATCTGT
GM-CSF	CATGTGAATGCCATCCAGGA	CAGGCCACATTCTCTCACTT
IGFBP-2	GCCCTCTGGAGCACCTCTACT	CATCTGCACTGTTGAGGTTGTAC